跳至主要内容
临床试验/NCT07392333
NCT07392333招募中不适用

A Prospective Cohort Study of Basivertebral Nerve Ablation Using the Stryker OptaBlate BVN System for the Treatment of Vertebrogenic Low Back Pain

Stryker Instruments1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2026年6月2日最近更新:
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
25
试验地点
1
主要终点
Change in functional disability, assessed by the mean improvement in Oswestry Disability Index (ODI) score

研究概览

简要总结

The goal of this observational study is to evaluate patient outcomes following treatment of vertebrogenic low back pain using the Stryker OptaBlate BVN System. Patients treated in accordance with the device IFU as part of routine clinical care and who consent to participate will be followed for 12 months after the procedure to assess treatment outcomes.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient scheduled for treatment with the OptaBlate BVN System in accordance with the device IFU and willing to participate in the clinical investigation, undergo study procedure, engage in follow-up, able to read, write, speak, and understand English, and able to provide written informed consent.

排除标准

  • The patient meets one or more contraindications as defined in the locally applicable IFU
  • Spinal fracture or history of spinal trauma at index levels
  • Previous lumbar fusion at any level
  • Prior basivertebral nerve ablation at the target levels
  • Vertebral cancer, spinal metastasis or Tumor-related vertebral fractures
  • History of Osteoporotic vertebral fractures
  • Spine interventions, including epidural steroid injections within 30 days
  • BMI > 40 kg/m²
  • Symptomatic spinal stenosis
  • Radicular pain or leg pain greater than back pain
  • Pregnancy or planning pregnancy during study period
  • Enrollment in another interventional clinical trial
  • Contraindication to MRI
  • Life expectancy of less than 12 months

研究组 & 干预措施

OptaBate BVN cohort

干预措施: Basivertebral nerve ablation (Device)

结局指标

主要结局

Change in functional disability, assessed by the mean improvement in Oswestry Disability Index (ODI) score

时间窗: 3 months post-procedure

Incidence and severity of adverse events related to the procedure and/or device.

时间窗: 12 months post-procedure

次要结局

  • Change in ODI(6 and 12 months post-procedure)
  • Change in Visual Analogue Score (VAS)(3, 6 and 12 months post-procedure)
  • Rate of patients achieving clinical success at 3 months, defined as ODI improvement ≥10 points and VAS reduction ≥2 cm(3 months post-procedure)
  • Change in health-related quality of life (36-item Short Form Survey Instrument (SF-36))(3, 6, and 12 months post-procedure)
  • Change in Pain Medication Dosage for Low Back Pain as Measured by Prescription Dosage Records(3, 6 and 12 months post-procedure)
  • Rate of additional procedures (lumbar transforaminal epidural steroid injections, lumbar interlaminar steroid injections, radiofrequency ablations etc.)(12 months post-procedure)
  • Imaging assessment - Magnetic Resonance Imaging (MRI) including Mean size of the lesion Rate of subjects with radiographic evidence of targeting success based on lesion location on MRI(6 weeks post-procedure)
  • Change in health-related quality of life (European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L))(3, 6 and 12 months post-procedure)
  • Assessment of global patient satisfaction(3, 6 and 12 months post-procedure)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验